Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. announced it will host a live conference call and audio webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET. The purpose of the call is to report financial results for the second quarter ended June 30, 2026, and to provide a business update. Access details for registration, dial-in, and webcast are provided.

Atea Pharmaceuticals announced positive topline results from its pivotal C-BEYOND Phase 3 trial for bemnifosbuvir/ruzasvir (BEM/RZR) in treating chronic Hepatitis C virus (HCV). The once-daily fixed-dose combination achieved its primary endpoint of statistical non-inferiority compared to the standard-of-care sofosbuvir/velpatasvir (SOF/VEL), demonstrating high cure rates across patient populations. BEM/RZR showed a 93.9% sustained virologic response (SVR) rate in the mITT population, with a shorter 8-week treatment duration for non-cirrhotic patients. The company anticipates sharing results from its second Phase 3 trial, C-FORWARD, in early 2027.

Atea Pharmaceuticals announced the initiation of a first-in-human Phase 1 clinical trial for AT-587, an oral antiviral nucleotide analog designed to treat Hepatitis E Virus (HEV) infection. HEV is a serious liver disease with no approved treatments, especially for at-risk immunocompromised populations. Preclinical data presented at EASL 2026 demonstrated AT-587's high antiviral potency against HEV, showing it to be significantly more potent than existing off-label treatments like ribavirin, and effective in an in vivo model.

Atea Pharmaceuticals announced the completion of patient enrollment in its C-FORWARD Phase 3 clinical trial for the treatment of hepatitis C virus (HCV) outside North America. The trial enrolled over 880 treatment-naïve patients across 17 countries, evaluating the bemnifosbuvir and ruzasvir (BEM/RZR) regimen. Topline results for C-FORWARD are anticipated around year-end 2026, while results for the C-BEYOND Phase 3 trial in North America are still expected mid-2026.

Atea Pharmaceuticals announced positive Phase 1 results for its fixed-dose combination bemnifosbuvir and ruzasvir (BEM/RZR) for hepatitis C virus (HCV), demonstrating a low risk of drug-drug interaction with commonly used medications like omeprazole and rosuvastatin. This supports simplified treatment for HCV patients. Additionally, the company presented preclinical data for AT-587, a potential first-in-class direct-acting antiviral for hepatitis E virus (HEV), showing high in vitro antiviral potency and in vivo efficacy. Atea plans to advance AT-587 into a first-in-human study mid-year.

Atea Pharmaceuticals announced the acceptance of three abstracts for presentation at the European Association for the Study of the Liver (EASL) Congress 2026. These include two posters supporting their fixed-dose combination regimen for Hepatitis C Virus (HCV) and a top poster presentation of preclinical data for AT-587, their lead clinical candidate for Hepatitis E Virus (HEV). The company highlighted that these presentations underscore progress across its antiviral pipeline and reinforce the potential for a best-in-class profile for their HCV regimen and a first-in-class therapy for HEV, with AT-587 expected to advance into clinical development mid-2026.

Atea Pharmaceuticals reported a net loss of $(45.4) million for the first quarter of 2026, an increase from $(34.3) million in the prior year, primarily due to a 39% rise in research and development expenses. The company continues its Phase 3 clinical development for its HCV product candidate, with topline results for C-BEYOND expected mid-2026 and C-FORWARD by year-end 2026, targeting an NDA submission in March 2027. Atea also plans to initiate Phase 1 clinical development for its HEV candidate, AT-587, in mid-2026, and maintains a cash runway sufficient for at least the next twelve months.

Atea Pharmaceuticals reported a net loss of $(45.4) million, or $(0.57) per share, for Q1 2026, compared to a net loss of $(34.3) million, or $(0.40) per share, in Q1 2025. Research and development expenses increased to $41.1 million. The company provided positive business updates, with its C-BEYOND Phase 3 HCV trial on track for mid-2026 topline results and C-FORWARD enrollment expected to complete mid-2026. Additionally, Atea plans to initiate a Phase 1 trial for its potential first-in-class Hepatitis E Virus candidate, AT-587, in mid-2026.

Atea Pharmaceuticals announced its 2026 Annual Meeting of Stockholders for June 18, 2026, with proposals including director elections and auditor ratification. The company provided a business update, highlighting the advancement of its HCV Phase 3 clinical trials with topline results expected mid-2026 and year-end 2026. Atea also expanded its pipeline with AT-587 for HEV, initiated a 25% workforce reduction for $15 million in savings, and completed a $25 million stock repurchase program.